Average glycated hemoglobin () levels decreased by 10 mmol/mol after 12 months of dulaglutide treatment in patients with type 2 diabetes.
At 12 months, average fasting plasma glucose () levels decreased by 24.9 mg/dL compared to baseline.
Body weight decreased by 3.4 kg and waist circumference decreased by 3.3 cm after 12 months of treatment.
Among patients who completed 24 months of follow-up, glycemic control stabilized after the initial decline observed in the first 12 months.
A total of 1130 patients completed 12 months of follow-up, while 270 completed 24 months.
Dulaglutide is administered once weekly using a simple auto-injector device.
Simplified
INTRODUCTION: Dulaglutide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA), became available in Italy in April 2016. The aim of ANDREW (Active Notes on Dulaglutide in the REal World), a multicenter, prospective, observational study, was to evaluate glycemic control and weight (co-primary outcomes) for up to 24 months in the real-life setting in consecutive outpatients with type 2 diabetes (T2D) who initiated dulaglutide. Co-secondary outcomes were durability of treatment effects on both glycated hemoglobin () and body weight.
METHODS: Overall, 1584 subjects (696 women, 888 men) with T2D (mean age [± standard deviation] 61.7 ± 10.2 years; mean T2D duration 9.9 ± 6.9 years) were treated with dulaglutide (0.75 or 1.5 mg once weekly) between April 2016 and December 2019.
RESULTS: A total of 1130 patients completed 12 months of follow-up, while 170 patients interrupted treatment before the 12-month endpoint. At 12 months, average HbA1c and average fasting plasma glucose () were significantly lower compared to baseline levels (- 10 mmol/mol and - 24.9 mg/dL, respectively), as were body weight (- 3.4 kg) and waist circumference (- 3.3 cm) values (all p < 0.0001). Among subjects that completed 24 months of follow-up (n = 270), the rapid decline in HbA1c and FPG values in the first 12 months was followed by stabilization in the following 12 months (p value for 12-24 months trend: 0.4 and 0.6, respectively).
CONCLUSIONS: Dulaglutide is an effective drug for the treatment of T2D that is administered once weekly using a simple auto-injector device. Real-life data confirm the observations in randomized controlled trials that persistent treatment with dulaglutide may help patients with T2D achieve an improvement in some metabolic features and in body weight. It is important that the benefits of therapy with dulaglutide, i.e., the effects of the "glycemic" and the so-called "extra-glycemic" actions of GLP-1RAs, are supported by diabetes care teams emphasizing the need for patients to maintain a healthy lifestyle.
Key numbers
10 mmol/mol
Decrease in
Average change from baseline at 12 months
24.9 mg/dL
Decrease in fasting plasma glucose
Average change from baseline at 12 months
3.4 kg
Weight loss
Average change from baseline at 12 months
Full Text
We can’t show the full text here under this license.
